Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00197145

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I Clinical Trial

Official title:
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00197145
Study type Interventional
Source ViiV Healthcare
Contact
Status Terminated
Phase Phase 3
Start date July 21, 2005
Completion date September 11, 2007
View Details
See also
  Status Clinical Trial Phase
Completed NCT03327740 - PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Completed NCT00257621 - GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults Phase 2
Completed NCT01227824 - A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Phase 3
Completed NCT01597648 - A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Phase 1
Completed NCT01205243 - ZIAGEN® Post-marketing Surveillance
Withdrawn NCT01283100 - A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects. Phase 1
Completed NCT00450580 - HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults Phase 3
Completed NCT00440947 - Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection Phase 3
Completed NCT00549198 - KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects Phase 4
Completed NCT00481390 - Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients N/A
Completed NCT00242840 - Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) Phase 3
Completed NCT00089583 - 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection Phase 2
Completed NCT00044577 - New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects Phase 3
Terminated NCT00104429 - GW873140 In Combination With Combivir In HIV Infected Subjects Phase 2
Completed NCT01263015 - A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Phase 3
Terminated NCT00102778 - GW873140 In Combination With Kaletra In HIV Infected Subjects Phase 2
Completed NCT00094523 - Fosamprenavir Versus Other Protease Inhibitors Phase 3
Completed NCT00046176 - A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients Phase 3
Terminated NCT00242879 - A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults Phase 2
Completed NCT00082394 - A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV Phase 4